Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current Assets
Cash and cash equivalents	$ 9,549	$ 17,116
Prepaid expenses and other current assets	559	827
Total Current Assets	10,108	17,943
Property and equipment, net	665	872
Deposits and other assets	23	23
Total Assets	10,796	18,838
Current Liabilities:
Accounts payable	879	2,020
Accrued expenses	1,485	1,526
Warrant liabilities	19	4,083
Accrued employee benefits	1,434	2,074
Deferred rent	97	90
Total Current Liabilities	3,914	9,793
Long term deferred rent	329	402
Total Liabilities	4,243	10,195
Series A convertible preferred stock, $0.001 par value; 10,000,000 and zero shares authorized; 120,000 issued and outstanding	12,234	12,053
Stockholders' Deficit:
Common stock, $0.001 par value; 200,000,000 and 10,000,000 shares authorized, 5,346,674 and 3,675,668 issued and 5,344,346 and 3,673,340 outstanding	5	4
Additional paid-in capital	200,807	192,670
Accumulated deficit	(204,545)	(194,170)
Total Synthetic Biologics, Inc. and Subsidiaries Deficit	(3,733)	(1,496)
Non-controlling interest	(1,948)	(1,914)
Total Stockholders' Deficit	(5,681)	(3,410)
Total Liabilities and Stockholders' Deficit	$ 10,796	$ 18,838